Business Context and Reporting Period
Company: Oaktree Acquisition Corp. III Life Sciences (a Cayman Islands exempted company and special purpose acquisition company).
Reporting Period: Quarter and six months ended June 30, 2026.
Status: The Company is a "blank check" company formed to effect a business combination. As of June 30, 2026, it has not selected a specific target and has not commenced operations. The Company has until October 25, 2026, to consummate a business combination or face mandatory liquidation.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Three Months Ended June 30, 2026 |
|---|---|---|
| Net Income | $2,998,742 | $1,604,621 |
| Operating Expenses (G&A) | $718,496 | $261,958 |
| Interest Income (Trust Account) | $3,717,238 | $1,866,579 |
| Cash (Outside Trust) | $1,179,670 | $1,179,670 |
| Cash Held in Trust Account | $205,280,770 | $205,280,770 |
| Working Capital Deficit | ($469,905) | ($469,905) |
| Total Liabilities | $8,748,581 | $8,748,581 |
| Deferred Underwriting Fees | $6,719,660 | $6,719,660 |
Material Changes vs. Prior Period
- Net Income Decline: Net income for the six months ended June 30, 2026, was $2,998,742, a decrease from $3,533,134 in the same period in 2025. This decline is primarily due to lower interest earned on the Trust Account ($3,717,238 vs. $4,247,746), reflecting changes in interest rates or timing.
- Operating Expenses: General and administrative expenses remained relatively stable, increasing slightly to $718,496 for the six months ended June 30, 2026, compared to $714,612 in the prior year period.
- Trust Account Growth: The Trust Account balance increased to $205,280,770 from $201,563,532 at December 31, 2025, driven by interest accretion.
- Cash Position: Cash held outside the Trust Account decreased to $1,179,670 from $1,434,965 at the end of the prior fiscal year, reflecting ongoing operational cash usage.
Outlook, Risks, and Contingencies
- Going Concern: The filing states that the Company's liquidity shortfall and the mandatory liquidation condition if a business combination is not completed by October 25, 2026, raise substantial doubt about its ability to continue as a going concern.
- Extension Requirement: If a business combination is not consummated by the deadline, the Company may seek an extension, which requires shareholder approval and would likely allow shareholders to redeem their shares, materially affecting the Trust Account balance.
- Related Party Support: The Company may need to raise additional capital through loans from the Sponsor or affiliates to meet working capital needs. There is no assurance such financing will be available.
- Geopolitical Risks: The filing highlights risks associated with military actions in Ukraine, the Middle East, and Venezuela, as well as changes in international trade policies, which could adversely affect the ability to complete a business combination.
- Subsequent Event: On July 21, 2026, the Company withdrew $250,000 from interest earned in the Trust Account for working capital needs.
Investor Verification Checklist
- Deadline Compliance: Verify the Company's progress toward a business combination before the October 25, 2026, deadline to avoid mandatory liquidation.
- Trust Account Yield: Monitor the interest rate environment and its impact on the Trust Account balance, which is the primary source of value for public shareholders.
- Related Party Loans: Review any new borrowings from the Sponsor or affiliates and the terms regarding conversion to equity or repayment.
- Redemption Rights: Understand the redemption thresholds and the potential impact of shareholder redemptions on the Company's ability to close a deal.
- Deferred Fees: Note the $6.7 million in deferred underwriting fees payable only upon successful completion of a business combination.